[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546949":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":39,"responsibleParty":114,"collaborators":116,"id":129,"slug":130,"hasResults":131,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":18,"eligibilityCriteria":135,"healthyVolunteers":131,"sex":136,"minAge":137,"maxAge":18,"enrollmentInfo":138,"targetDuration":18,"studyType":141,"phases":142,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":58,"whyStopped":18,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"Odense University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Discontinue OAC","EXPERIMENTAL","OAC stopped for the duration of the trial",[13],"Drug: OAC will be discontinued for the duration of the trial",{"label":15,"type":16,"description":17,"interventionNames":18},"Continue OAC","NO_INTERVENTION","OAC continued for the duration of the trial",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","OAC will be discontinued for the duration of the trial","Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban",[9],[26],{"name":27,"affiliation":5,"role":28},"Lars Peter Riber, DMSc","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},"Kristina Gosvig, M.D.","CONTACT","+4551520696","kristina.gosvig@rsyd.dk",{"name":36,"role":32,"phone":37,"phoneExt":18,"email":38},"Julie Goller, M.D.","22951855","julie.goller@outlook.com",[40,56,68,80,92,104],{"facility":41,"status":42,"city":43,"state":44,"zip":18,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Rigshospitalet","NOT_YET_RECRUITING","Copenhagen","Capital Region","Denmark","DK",{"type":48,"coordinates":49},"Point",[50,51],12.56553,55.67594,{"lat":51,"lon":50},[54],{"name":55,"role":32,"phone":18,"phoneExt":18,"email":18},"Christian Carranza, M.D.",{"facility":57,"status":58,"city":59,"state":44,"zip":18,"country":45,"countryCode":46,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Gentofte Hospital","RECRUITING","Gentofte Municipality",{"type":48,"coordinates":61},[62,63],12.54601,55.74903,{"lat":63,"lon":62},[66],{"name":67,"role":32,"phone":18,"phoneExt":18,"email":18},"Kristian Eskesen, MD",{"facility":69,"status":42,"city":70,"state":71,"zip":18,"country":45,"countryCode":46,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Regionshospital Gødstrup","Herning","Central Jutland",{"type":48,"coordinates":73},[74,75],8.97662,56.13615,{"lat":75,"lon":74},[78],{"name":79,"role":32,"phone":18,"phoneExt":18,"email":18},"Morten Böttcher, M.D.",{"facility":81,"status":42,"city":82,"state":83,"zip":18,"country":45,"countryCode":46,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Aalborg university hospital","Aalborg","North Denmark",{"type":48,"coordinates":85},[86,87],9.9187,57.048,{"lat":87,"lon":86},[90],{"name":91,"role":32,"phone":18,"phoneExt":18,"email":18},"Louise Rasmussen, M.D.",{"facility":93,"status":58,"city":94,"state":95,"zip":18,"country":45,"countryCode":46,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Århus Universitetshospital","Aarhus","Region Midt",{"type":48,"coordinates":97},[98,99],10.21076,56.15674,{"lat":99,"lon":98},[102],{"name":103,"role":32,"phone":18,"phoneExt":18,"email":18},"Ivy Modrau, MD",{"facility":5,"status":58,"city":105,"state":106,"zip":18,"country":45,"countryCode":46,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Odense","Region Syddanmark",{"type":48,"coordinates":108},[109,110],10.38831,55.39594,{"lat":110,"lon":109},[113],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},{"type":115,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[117,119,121,123,125,127],{"name":118,"class":6},"Rigshospitalet, Denmark",{"name":120,"class":6},"Gødstrup Hospital",{"name":122,"class":6},"Aarhus University Hospital",{"name":124,"class":6},"Aalborg University Hospital",{"name":126,"class":6},"Population Health Research Institute",{"name":128,"class":6},"Region of Southern Denmark","100546949","phase-4-can-patients-with-atrial-fibrillation-safely-discontinue-anticoagulant-therapy-after-cardiac-surgery-atlaac-100546949",false,"NCT06401616","Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)","Anticoagulant Therapy in Patients With Atrial Fibrillation After Surgical Left Atrial Appendage Closure: a Randomized Non-inferiority Trial (The ATLAAC Trial)","Inclusion Criteria:\n\n* Age \\> 18 years\n* Previously undergone any type of cardiac surgical procedure including any type of surgical LAA closure (use of any of the following techniques; amputation and suture closure, stapler closure, non-amputating suture closure or closure with an approved surgical occlusion device (e.g. AtriClip)) according to the NationalPatient Register (NPR), the Danish Heart Registry (DHR) or the Western Danish Heart Registry (WDHR) from January 1st 2010 til 3 months prior to inclusion in the project.\n* Documented history of paroxysmal, persistent, or permanent atrial fibrillation or atrial flutter according to the electronic patient record\n* Informed consent\n\nExclusion Criteria:\n\n* Not receiving OAC (warfarin\u002FDOAC)\n* Patient specific conditions requiring OAC (e.g.mechanical valve, previous pulmonary embolism)\n* Renal impairment (estimated glomerular filtration rate \\\u003C 30)\n* Allergy to contrast media\n* Pregnancy or breastfeeding","ALL","18 Years",{"count":139,"type":140},1220,"ESTIMATED","INTERVENTIONAL",[143],"PHASE4","Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery. The procedure significantly reduces the risk of stroke and systemic embolism, which may render anticoagulation unnecessary or even harmful when considering the associated increased risk of bleeding. A clinical trial to address the need for anticoagulation after LAA closure is needed.\n\nThe ATLAAC trial will enroll 1220 patients with atrial fibrillation who have previously undergone surgical LAA closure. Patients will undergo a cardiac CT-scan to determine if LAA closure was successful and patients with successful closure will be randomized to continue or discontinue anticoagulation. The trial will assess the risk of ischemic stroke, peripheral arterial embolism, and major bleeding during the randomized intervention",[146,147,148],"Atrial Fibrillation","Left Atrial Appendage Absent","Anticoagulant Adverse Reaction",[150,151,152,153],"Atrial fibrillation","Anticoagulant treatment","Surgical left atrial appendage closure","surgical left atrial appendage occlusion","2024-05-22",{"date":156,"type":157},"2024-05-23","ACTUAL",{"date":159,"type":157},"2024-05-21",{"date":161,"type":140},"2028-03",{"name":5,"class":6},6]